BRAF and melanoma: Despite initial survival benefit, approximately half of all patients treated with anti-BRAF agents exhibits disease progression within 6–9 months after starting treatment: mechanisms of resistance to BRAF inhibitors are better known in melanoma and colorectal cancer and include genetic and epigenetic events leading to intrinsic primary or acquired secondary resistance (92–95).